Poster Hall
Sponsored by AbbVie Medical Affairs
What's Hot
View all perspectives
Mrinalini Dey DrMiniDey
1 month ago
SmPCs recommend interrupting immunosuppression (IS) in infection
What happens if you continue the drug?
Ab2611 found no difference in infection outcomes btwn temp interruption & continuation of IS in infection
Could continuation be a safe option in some pts?
#ACR24 @RheumNow https://t.co/14SN6a4Wm8
Dr. John Cush RheumNow
1 month ago
RIP to Glucocorticoids in GPA
For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA).
https://t.co/WqpO6ACqtu https://t.co/vb8qx3uHA0
A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a population where 10-20% progress to ESRD within five years, even with immunosuppressive therapies.
Dr. John Cush RheumNow
1 month ago
Evaluation of Bimekizumab in PsA
At last year’s ACR, I shared about the early clinical trial data on bimekizumab in psoriatic arthritis. Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2… https://t.co/lphZUiiq5T https://t.co/zuHpBaMtEv
Dr. John Cush RheumNow
1 month ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis.All content is chosen by RheumNow & its faculty
Bella Mehta bella_mehta
1 month ago
Study on #SLE and ESRD using machine learning:
Developed model to identify patients with SLE and ESRD
Used NIH 'All of Us' dataset
XGBoost outperformed Random Forest
SDOH data improved model precision #ACR24 @rheumnow #MachineLearning abst#1876 https://t.co/PQ7u4Pj5OH
Richard Conway RichardPAConway
1 month ago
Wang et al. Propensity score matched cohort study. 63,302 individuals. Colchicine associated lower risk of THR/TKR, HR 0.87. @RheumNow #ACR24 Abstr#2557 https://t.co/UUU3Tm67ML https://t.co/uKi0e8E7HV
Eric Dein ericdeinmd
1 month ago
@RheumNow interview at #ACR24 with Dr Harry Hurley about A#1694
Should we do one or two lungs when transplanting for autoimmune related ILD?
https://t.co/2omSSAPvgi https://t.co/BlAQjuBRFt
Richard Conway RichardPAConway
1 month ago
Zou et al. Phase 2 RCT Vunakizumab, humanized IL17A in PsA. 12 week study. ACR responses shown in figure, looks similar to existing IL17As. @RheumNow #ACR24 Abstr#2581 https://t.co/Td5xlMYrAd https://t.co/Rl4gkmDFOR
Dr. John Cush RheumNow
1 month ago
How Online Searches Reveal Patient Needs
In the digital age, managing health conditions is rapidly evolving as patients increasingly turn to online resources for answers—over 65% search for health-related questions online. #ACR24
https://t.co/AbHGNAsIpH https://t.co/nuoQeigJfE
